Noven Pharmaceuticals, a Miami developer of drug-patch technologies and products, agreed to acquire privately held JDS Pharmaceuticals of New York for $125 million. JDS specializes in neurological drugs, including its antidepressant Pexeva and a timed-release form of lithum for bipolar disorder.
JDS was backed by Galen Partners and Altaris Capital Partners.